ArticleACS chemical neuroscience2022
Structural and Molecular Insight into Piperazine and Piperidine Derivatives as Histamine H
Abstract read
In one paragraph
Article in ACS chemical neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Modulation of Tau Protein Neurotoxic Hallmarks by Novel σChemMedChem · 2026Article
- Multitargeted Aza-Arylcarboxamides for Neurodegenerative Diseases: Potent Histamine HACS chemical neuroscience · 2026Article
- Structural Basis for D3/D4-Selective Antagonism of Piperazinylalkyl Pyrazole/Isoxazole Analogs.Molecules (Basel, Switzerland) · 2025Article
- Recent Advances in the Development of Sigma Receptor (Radio)Ligands and Their Application in Tumors.ACS pharmacology & translational science · 2025Review
- Xylazine as an emerging new psychoactive substance; focuses on both 5-HTArchiv der Pharmazie · 2025Article
- 2-{International journal of molecular sciences · 2025Article
- Design, Synthesis, and Evaluation of Novel (-)-cis-N-Normetazocine Derivatives: In Vitro and Molecular Modeling Insights.Chemical biology & drug design · 2024Article
- An Integrated Computational Approaches for Designing of Potential Piperidine based Inhibitors of Alzheimer Disease by Targeting Cholinesterase and Monoamine Oxidases Isoenzymes.Applied biochemistry and biotechnology · 2024Article
- A protocol for controlled reactivity shift in the 2,2-difluorovinyl motif used for selective S-Communications chemistry · 2024Article
- Novel object recognition test as an alternative approach to assessing the pharmacological profile of sigma-1 receptor ligands.Pharmacological reports : PR · 2023Article
- Dual Piperidine-Based Histamine HJournal of medicinal chemistry · 2023Article
- Migraine, Allergy, and Histamine: Is There a Link?Journal of clinical medicine · 2023Review
- Synthesis, Computational Insights, and Evaluation of Novel Sigma Receptors Ligands.ACS chemical neuroscience · 2023Article
- Evaluation of Some Safety Parameters of Dual Histamine HInternational journal of molecular sciences · 2023Article
- Computer-Assisted Design of Peptide-Based Radiotracers.International journal of molecular sciences · 2023Review
- Steered Molecular Dynamics Simulations Study on FABP4 Inhibitors.Molecules (Basel, Switzerland) · 2023Article
- 1,2-Dibenzoylhydrazine as a Multi-Inhibitor Compound: A Morphological and Docking Study.International journal of molecular sciences · 2023Article
- The Chemotype of Chromanones as a Privileged Scaffold for Multineurotarget Anti-Alzheimer Agents.ACS pharmacology & translational science · 2022Article
- KSK-74: Dual Histamine HInternational journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Katarzyna SzczepańskaDepartment of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, Kraków 30-688, Poland.
Sabina PodlewskaDepartment of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, Kraków 30-688, Poland.ORCID 0000-0002-2891-5603
Maria DichiaraDepartment of Drug and Health Sciences, University of Catania, V.le A. Doria, 95125 Catania, Italy.
Davide GentileDepartment of Drug and Health Sciences, University of Catania, V.le A. Doria, 95125 Catania, Italy.
Vincenzo PatamiaDepartment of Drug and Health Sciences, University of Catania, V.le A. Doria, 95125 Catania, Italy.ORCID 0000-0002-0048-2631
Niklas RosierInstitute of Pharmacy, Faculty of Chemistry and Pharmacy, University of Regensburg, Universitätsstraße 31, D-93053 Regensburg, Germany.
Denise MönnichInstitute of Pharmacy, Faculty of Chemistry and Pharmacy, University of Regensburg, Universitätsstraße 31, D-93053 Regensburg, Germany.
Ma Carmen Ruiz CanteroDepartment of Pharmacology and Neurosciences Institute (Biomedical Research Center) and Biosanitary Research Institute ibs.GRANADA, University of Granada, Avenida de la Investigación 11, 18016 Granada, Spain.ORCID 0000-0001-6968-0946
Tadeusz KarczDepartment of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, Kraków 30-688, Poland.
Dorota ŁażewskaDepartment of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, Kraków 30-688, Poland.
Agata SiwekDepartment of Pharmacobiology, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, Kraków 30-688, Poland.
Steffen PockesInstitute of Pharmacy, Faculty of Chemistry and Pharmacy, University of Regensburg, Universitätsstraße 31, D-93053 Regensburg, Germany.ORCID 0000-0002-2211-9868
Enrique J CobosDepartment of Pharmacology and Neurosciences Institute (Biomedical Research Center) and Biosanitary Research Institute ibs.GRANADA, University of Granada, Avenida de la Investigación 11, 18016 Granada, Spain.
Agostino MarrazzoDepartment of Drug and Health Sciences, University of Catania, V.le A. Doria, 95125 Catania, Italy.ORCID 0000-0002-8728-8857
Holger StarkInstitute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, Universitaetsstr. 1, 40225 Duesseldorf, Germany.ORCID 0000-0003-3336-1710
Antonio RescifinaDepartment of Drug and Health Sciences, University of Catania, V.le A. Doria, 95125 Catania, Italy.ORCID 0000-0001-5039-2151
Andrzej J BojarskiMaj Institute of Pharmacology, Polish Academy of Sciences, Smętna 12, Kraków 31-343, Poland.ORCID 0000-0003-1417-6333
Emanuele AmataDepartment of Drug and Health Sciences, University of Catania, V.le A. Doria, 95125 Catania, Italy.ORCID 0000-0002-4750-3479
Katarzyna Kieć-KononowiczDepartment of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, Kraków 30-688, Poland.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In an attempt to extend recent studies showing that some clinically evaluated histamine H
Indexed as
Histamine H3 AntagonistsReceptors, Histamine H3AnalgesicsHistamineHistamine AntagonistsLigandsPiperazinePiperidinesReceptors, sigmaSigma-1 ReceptorStructure-Activity RelationshipAnalgesicsHistamineHistamine AntagonistsHistamine H3 AntagonistsLigandsPiperazinePiperidinesReceptors, Histamine H3Receptors, sigmaSigma-1 Receptordual targeting compoundsdynamicsfunctional characterizationhistamine H3 receptormolecular dockingpiperazine derivativespiperidine derivativessigma-1 receptorsigma-2 receptor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.